🇺🇸 FDA
Patent

US 9896509

Use of antagonists of the interaction between HIV GP120 and α4β7 integrin

granted A61KA61K2039/505A61K38/12

Quick answer

US patent 9896509 (Use of antagonists of the interaction between HIV GP120 and α4β7 integrin) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Feb 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K2039/505, A61K38/12, A61K39/3955, A61K45/06